Health Condition 1: L659- Nonscarring hair loss, unspecified
Conditions
Interventions
None listed
Sponsors
Namaskar Ayurved Private Limited
Eligibility
Inclusion criteria
Inclusion criteria: 1. Subjects suffering from mild to moderate hair loss (40-140 Hair by Comb test and Finger Test). 2. Subjects who are infrequent hair oil users 3. Subjects who are willing to give informed consent and ready to comply with the protocol 4. Subjects who are ready to provide regular follow ups till the completion of the study.
Exclusion criteria
Exclusion criteria: 1. Subjects with severe Hair fall due to any clinically significant disorder/s like anemia, thyroid disorders etc. 2. Subject with severe dermatological disorders of the scalp that might interfere with the study evaluation 3. Subjects with recent disease history like, malaria, typhoid, jaundice and scalp diseases and subjects who in the opinion of the investigator are not eligible for enrollment in the clinical study 4. Subjects who have regularly used anti-hair fall treatment with hair oils over the last 6 months. 5. Subjects who have previously undergone hair transplantation procedures 6. Subjects on systemic steroids for more than 14 days within 2 months prior to enrollment. 7. Subjects on immunosuppressive drugs 8. Known cases of Hypersensitivity to hair oil contents 9. Subjects who have participated in any other clinical study since last 3 months 10. Subjects who are reported pregnant/planning a pregnancy or lactating. 11. Menopausal Women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.Comparative assessment of hair fall by running finger test 2.Comparative assessment of hair breakage by comb test Timepoint: Screening visit, Baseline visit, Day 15, Day 30, Day 45 and Day 60 | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Comparative assessment of hair fall by Hair Pull test 2. Comparative assessment of hair growth 3. Comparative assessment of effect on dandruff 4. Comparative assessment of effect on quality of hair 5. Global assessment of overall change by physician and subject 6. Assessment of safety and adverse events Timepoint: Screening visit, Baseline visit, Day 15, Day 30, Day 45 and Day 60 | — |
Countries
India
Contacts
Public ContactDr Sanjay Tamoli
Target Institute of Medical Education and Research Pvt. Ltd
Outcome results
None listed